The primary outcome
SECONDARY
The ITT analysis was conducted to evaluate and determine that CPT-FPV exhibited non-inferiority compared to sotrovimab in terms of preventing hospitalization within 14 and 28 days [The intention to treat analysis of non-inferiority of primary endpoints between COVID-19 convalescent plasma therapy/favipiravir and sotrovimab.Intention to treat analysis comparing the primary and secondary clinical outcomes of mild-to-moderate COVID-19 patients treated with convalescent plasma/favipiravir versus those treated with sotrovimabData are presented as frequency and percentage for each parameter. Differences in proportions between the two treatment groups are provided with their 95% confidence interval.

Calculations were done using the Pearson chi-squared test or.Fisher’s exact test where appropriate.